The role of the IL-23/IL-17 pathway in the pathogenesis of plaque psoriasis is clearly validated by the clinical success of antibodies neutralizing IL-23p19, IL-17A or the IL-17A receptor. This evidence concerns the gene IL17A and psoriasis vulgaris.